Trial Profile

A phase IIb sudy assessing six weeks of CC-31244 along with six weeks treatment of Sofosbuvir/velpatasvir

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CC 31244 (Primary) ; Sofosbuvir/velpatasvir (Primary)
Indications Hepatitis C
Focus Adverse reactions

Most Recent Events

30 Mar 2020 According to a Cocrystal Pharma media release, partnering effort underway for this study is expected in Q4 in 2020.
19 Nov 2019 New trial record
12 Nov 2019 According to a Cocrystal Pharma media release, this toxicology study will commence in the second half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com